文献速递心血管MR

中度或重度主动脉瓣反流心脏不良重构的分期

Staging of Cardiac Adverse Remodeling in Moderate or Severe Aortic Regurgitation.
PubMed 文献 · JACC Cardiovasc Imaging · 2025-08-05

研究前瞻性纳入395例中重度主动脉瓣反流患者,采用基于心脏磁共振的四级心脏重构分期系统,分期越高年化死亡率越高,右心重构者风险最高,调整反流严重程度、主动脉瓣置换和EuroSCORE II后分期仍与死亡率独立相关。

要点

  • 基于心脏磁共振的四级心脏重构分期可对中重度主动脉瓣反流患者进行预后分层。
  • 分期每增加一级,全因死亡风险调整后HR为1.69(95%CI 1.28-2.23)。
  • 右心重构(3期)患者年化死亡率最高,为7.25% per year。

核心结论

  • 基于心脏磁共振表现的心脏重构分期系统在中重度主动脉瓣反流患者中提供增量预后价值,调整手术风险、主动脉瓣置换和反流严重程度后仍成立。
  • 主动脉瓣反流中的右心重构与最高死亡率相关。
  • 进一步研究可确定该分期系统是否有助于指导患者管理和干预时机。

研究设计与样本

  • 前瞻性队列研究,患者来自DEBAKEY-CMR研究(DeBakey心血管磁共振研究;NCT04281823),纳入时间为2009年至2020年。
  • 共纳入395例经心脏磁共振诊断为中度或重度主动脉瓣反流的患者,排除原发性心肌病(如肥厚型心肌病、淀粉样变性、结节病)或既往瓣膜干预者。
  • 分期定义:0期无心脏重构;1期左心室重构;2期二尖瓣或左心房异常;3期右心重构。
  • 结局为全因死亡,平均随访3.9 ± 2.9年。

诊断标准与关键数值

  • 分期标准:0期无心脏重构;1期左心室重构;2期二尖瓣或左心房异常;3期右心重构。
  • 分期分布:0期32例(8.10%)、1期146例(37.0%)、2期77例(19.5%)、3期140例(35.4%)。
  • 年化死亡率:0期0.68% per year、1期2.25% per year、2期3.76% per year、3期7.25% per year(趋势P < 0.001)。
  • 调整反流严重程度、主动脉瓣置换和EuroSCORE II后,分期每增加一级与死亡风险增加独立相关:调整后HR 1.69(95%CI 1.28-2.23),P < 0.001。

临床应用与阅片要点

  • 在中重度主动脉瓣反流患者的心脏磁共振报告中,可按0至3期描述心脏重构范围,以辅助预后分层。
  • 右心重构(3期)提示最高死亡风险。
  • 原文指出进一步研究可确定该分期系统是否有助于指导患者管理和干预时机。

局限性

  • 原文指出进一步研究可确定该分期系统是否有助于指导患者管理和干预时机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: A recently proposed staging system for cardiac structural and functional abnormalities demonstrated incremental prognostic value in aortic stenosis.

OBJECTIVES: The authors investigate a staging system incorporating cardiac magnetic resonance (CMR) in moderate or severe aortic regurgitation (AR).

METHODS: Patients prospectively enrolled in DEBAKEY-CMR (DeBakey Cardiovascular Magnetic Resonance Study; NCT04281823) between 2009 and 2020 who had moderate or severe AR by CMR were studied. We excluded patients with a primary cardiomyopathy (eg, hypertrophic cardiomyopathy, amyloidosis, sarcoidosis) or prior valve intervention. The stages were defined as stage 0: no cardiac remodeling; stage 1: left ventricular (LV) remodeling; stage 2: mitral valve or left atrial abnormalities; and stage 3: right heart remodeling. The outcome was all-cause mortality.

RESULTS: The authors studied 395 patients, median age 62 years (Q1-Q3: 51-72 years); 79.2% were male, and 25.8% had bicuspid aortic valve. Thirty-two patients (8.10%) were classified as stage 0, 146 (37.0%) as stage 1, 77 (19.5%) as stage 2, and 140 (35.4%) as stage 3. Over a mean follow-up period of 3.9 ± 2.9 years, the annualized mortality rate was 0.68% per year in stage 0, 2.25% per year in stage 1, 3.76% per year in stage 2, and 7.25% per year in stage 3 (P for trend of mortality <0.001). The extent of cardiac remodeling was independently associated with increased hazard for mortality (adjusted HR: 1.69 per increment of stage [95% CI: 1.28-2.23]; P < 0.001) after adjusting for regurgitation severity, aortic valve replacement (AVR), and EuroSCORE II (European System for Cardiac Operative Risk Evaluation). Patients with right heart remodeling had the highest hazard for events.

CONCLUSIONS: A cardiac remodeling staging system incorporating CMR findings provides incremental prognostication in AR after adjusting for surgical risk, AVR, and regurgitation severity. Right heart remodeling in AR was associated with the highest mortality. Further research can determine whether the staging system could aid in guiding patient management and the timing of intervention.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Malahfji M, Nguyen DT, Bhugra P, et al. Staging of Cardiac Adverse Remodeling in Moderate or Severe Aortic Regurgitation. JACC Cardiovasc Imaging. 2025. PMID: 40758076. doi:10.1016/j.jcmg.2025.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。